Interactive Investor
>>

Incyte Corp (NASDAQ:INCY) Share Price

INCY

Incyte Corp

North American company

Right Arrow 1

Healthcare

Right Arrow 2

Biotechnology

 / 

- / -
-
- / -
-
-
-

NAV Price

-

Last Traded

-

Chg

-

-

XNAS

-

Updated: -

Loading...

Times are shown in GMT-4, values are delayed by at least 15 minutes. Past performance is not a reliable indicator of future results.

This stock can be held in:

 / 

- / -
-
- / -
-
-
-

Company Profile

Incyte focuses on the discovery and development of small-molecule drugs. The firm's lead drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis. Incyte's pipeline includes a broad array of oncology and dermatology programs.Incyte Corp is a biopharmaceutical company. It discovers, develops and commercializes proprietary therapeutics. Its product JAKAFI, a JAK1 and JAK2 inhibitor is used for treatment of patients with intermediate or high risk myelofibrosis.

NASDAQ:INCY

US45337C1027

USD

Loading...

Loading Comparison